tiprankstipranks
Trending News
More News >

Shandong Xinhua Pharmaceutical Releases 2024 Financial Results

Story Highlights
  • Shandong Xinhua operates in the pharmaceutical industry, producing and selling drugs.
  • The company announced its audited 2024 financial results, adhering to Chinese standards.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Shandong Xinhua Pharmaceutical Releases 2024 Financial Results

Confident Investing Starts Here:

Shandong Xinhua Pharmaceutical Company Limited Class H ( (HK:0719) ) has provided an announcement.

Shandong Xinhua Pharmaceutical Company Limited has announced its audited consolidated financial results for the year ending December 31, 2024. The results, prepared in accordance with China Accounting Standards for Business Enterprises, reflect the company’s ongoing commitment to transparency and adherence to regulatory standards, potentially impacting its market positioning and stakeholder confidence.

More about Shandong Xinhua Pharmaceutical Company Limited Class H

Shandong Xinhua Pharmaceutical Company Limited is a joint stock company based in the People’s Republic of China, operating within the pharmaceutical industry. The company is involved in the production and sale of pharmaceutical products and is listed on both the Hong Kong Stock Exchange and the Shenzhen Stock Exchange.

YTD Price Performance: -0.69%

Average Trading Volume: 3,436,257

Technical Sentiment Signal: Strong Sell

Current Market Cap: HK$9.16B

See more insights into 0719 stock on TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App